Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
Why Evotec is on investors' radar today
Evotec (XTRA:EVT) has caught attention after a sharp share price move, with the stock up about 23% over the past week and roughly 27% over the past month.
This short term strength contrasts with weaker performance over the past 3 months and past year. This has prompted investors to reassess the company's €5.57 share price against its fundamentals and recent financial results.
See our latest analysis for Evotec.
The sharp 7 day share price return of 23.07% and 30 day return of 26.94% sit against a weaker 1 year total shareholder return of 12.91%, so recent momentum contrasts with longer term losses.
If this rebound has you looking beyond a single name, it could be a good moment to scan other opportunities using Simply Wall St's screener for 126 healthcare AI stocks
With Evotec trading at €5.57, a large intrinsic discount estimate and a lower share price than many analysts' targets, the key question is whether this is a genuine value opportunity or if the market already prices in any future recovery.
Most Popular Narrative: 19.5% Undervalued
Evotec's most followed narrative puts fair value at €6.92, above the current €5.57 share price, and builds that view around long term revenue and margin assumptions.
Evotec's expansion and deepening of large pharma partnerships, as evidenced by the rapid growth of its Just, Evotec Biologics (JEB) business with three major pharma clients and a move to an asset lighter, technology focused licensing model, are expected to drive recurring, higher margin revenue streams, supporting revenue growth and boosting net margins.
Curious what sits behind that optimism? The narrative leans heavily on projected revenue expansion, a swing from losses to profits, and a future earnings multiple that assumes meaningful execution.
Result: Fair Value of €6.92 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on early stage biotech funding and key partnerships holding up. Any pullback there could quickly challenge the upbeat revenue story.
Find out about the key risks to this Evotec narrative.
Next Steps
The mixed tone of this article, with clear risks and some potential upside, means the real question is how you interpret the same facts. Take a moment to review the data and form your own judgment with the help of 2 key rewards and 1 important warning sign.
Looking for more investment ideas?
If Evotec has sharpened your focus, do not stop here; widen your watchlist now so you are not the one hearing about opportunities after they move.
-
Target potential mispricings by scanning companies that combine quality fundamentals with attractive valuations through the 224 high quality undervalued stocks .
-
Strengthen your defense by reviewing the 297 resilient stocks with low risk scores and see which names score well on resilience and risk controls.
-
Get ahead of the crowd by searching the screener containing 574 high quality undiscovered gems and spot underfollowed businesses before they hit everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include EVT.DE .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
